General Surgery, Istituto Ortopedico Rizzoli, Bologna, Italy.
Surg Oncol. 2010 Dec;19(4):193-9. doi: 10.1016/j.suronc.2009.05.002. Epub 2009 Jun 9.
Approximately one-third of patients with localized osteosarcoma at presentation relapse as well as about three-fourths of the patients with metastases at diagnosis, about 90% of relapses are lung metastases. The role of lung metastasectomy remains to be determined.
and methods: Three hundred and twenty three patients, 88 with resectable lung metastases at diagnosis and 235 with localized disease at presentation who relapsed with lung metastases were treated.
A total of 498 lung surgeries and 607 thoracotomies were performed. The 5 year overall survival was 37%. Final outcome was significantly related to presence or absence of metastasis, time of first relapse and presence of local recurrences. According to stage of the disease, the rate of a 5 year event-free survival (EFS) was 36% for patients with localized disease who later relapsed and 9% for patients with resectable lung metastases at presentation (p<0.0001). However, there were no differences in EFS between patients who underwent two or three thoracotomies and patients who had four or five thoracotomies (7.5 vs 18.7%, p=0.29).
In patients with recurrent resectable pulmonary metastases from high grade osteosarcoma treated with adjuvant or neoadjuvant chemotherapy, thoracotomy should always be considered regardless the number of previous lung relapses and the number of secondary pulmonary lesions.
大约三分之一的局部骨肉瘤患者在就诊时复发,约四分之三的转移性骨肉瘤患者在诊断时就发生转移,约 90%的复发是肺转移。肺转移瘤切除术的作用仍有待确定。
共治疗了 323 例患者,其中 88 例在诊断时存在可切除的肺转移灶,235 例在就诊时存在局限性疾病但发生了肺转移灶。
共进行了 498 例肺手术和 607 例开胸手术。5 年总生存率为 37%。最终结果与转移灶的存在与否、首次复发的时间以及局部复发的存在显著相关。根据疾病分期,局限性疾病患者在发生肺转移后的 5 年无事件生存率(EFS)为 36%,而在诊断时可切除肺转移灶的患者为 9%(p<0.0001)。然而,接受两次或三次开胸手术的患者与接受四次或五次开胸手术的患者之间 EFS 无差异(7.5%比 18.7%,p=0.29)。
对于接受辅助或新辅助化疗治疗的复发性可切除肺高级别骨肉瘤患者,无论之前的肺复发次数和继发性肺病变数量如何,都应始终考虑开胸手术。